Trial Profile
An Investigation of the relationship between adverse event and efficacy of treatment with lenvatinib in patients with unresectable hepatocellular carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 14 Nov 2022 Status changed from recruiting to completed.
- 16 Nov 2018 New trial record